• Publications
  • Influence
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.
Parkinson's disease is a movement disorder characterized by death of dopaminergic substantia nigra (SN) neurons and brain accumulation of α-synuclein. The tyrosine kinase Abl is activated inExpand
  • 181
  • 9
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with LewyExpand
  • 115
  • 9
  • PDF
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
BackgroundTreatment of mild-moderate Alzheimer’s disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines inExpand
  • 196
  • 7
  • PDF
Parkin Ubiquitinates Tar-DNA Binding Protein-43 (TDP-43) and Promotes Its Cytosolic Accumulation via Interaction with Histone Deacetylase 6 (HDAC6)*
Background: TDP-43 pathology and the role of E3 ubiquitin ligases are increasingly recognized in neurodegeneration. Results: Parkin ubiquitinates TDP-43 and forms a multiprotein complex with HDAC6 toExpand
  • 82
  • 6
Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
Tyrosine kinase inhibitors (TKIs) are effective therapies for leukaemia. Alzheimer is a neurodegenerative disease characterized by accumulation of β‐amyloid (plaques) and hyper‐phosphorylated TauExpand
  • 80
  • 4
  • PDF
Resveratrol for Alzheimer's disease
The amyloid hypothesis suggests that the progressive accumulation and deposition of central nervous system (CNS) amyloid with aging is the proximate cause of Alzheimer's disease (AD). Thus, targetingExpand
  • 99
  • 3
Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy
Objectives Neuro-inflammation is common in α-Synucleinopathies and Tauopathies; and evidence suggests a link between the tyrosine kinase Abl and neurodegeneration. Abl upregulates α-Synuclein andExpand
  • 34
  • 3
  • PDF
Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson’s disease
Parkinson's disease (PD) is a motor disorder that involves death of dopaminergic neurons in the substantia nigra pars compacta. Parkin is an autosomal recessive gene that is mutated in early onsetExpand
  • 46
  • 3
Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance
The effects of ABL1/ABL inhibition on clearance of SNCA/α-synuclein were evaluated in animal models of α-synucleinopathies. Parkinson disease (PD) is a movement disorder characterized by death ofExpand
  • 38
  • 2
Parkin reverses TDP‐43‐induced cell death and failure of amino acid homeostasis
The E3 ubiquitin ligase Parkin plays a central role in the pathogenesis of many neurodegenerative diseases. Parkin promotes specific ubiquitination and affects the localization of transactivationExpand
  • 30
  • 2